Company intelligence / Profile preview

AMO Pharma

Leeds, England, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

AMO Pharma's lead program, tideglusib (AMO-02), has advanced to Phase 3 for congenital myotonic dystrophy (DM1) after successful Phase 2 results. Other pipeline drugs, such as AMO-04 and diazepinomicin (AMO-01), are in Phase 2 for rare neurodevelopmental diseases including Rett syndrome and Fragile X syndrome. The company focuses on rare pediatric neurogenetic disorders.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Numedicus Limited (Development and license agreement on AMO-04 for Rett syndrome and breathing disorders)

Beyond the preview

Go deeper on AMO Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMO Pharma.

Explore the full profile